CLEVELAND, Nov. 15 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), announced today that CEO Michael Fonstein, Ph.D., was interviewed yesterday by Wall Street Reporter. The audiocast can be accessed at the Cleveland BioLabs website at http://www.cbiolabs.comor at for 30 days.

Mr. Fonstein discussed the Company's proprietary technology platform, lead compounds and recent updates.

Cleveland BioLabs' development efforts are based on discoveries made in connection with the investigation of the cell-level process known as apoptosis. Apoptosis is a highly specific and tightly regulated form of cell death that can occur in response to external events such as exposure to radiation or toxic chemicals or to internal stresses.

Through the Company's internal research and development efforts and its strategic partnerships, CBLI has established a technological foundation for the development of new pharmaceuticals and their rapid pre-clinical evaluation. The Company has acquired rights to develop and commercialize two classes of prospective drugs.

Protectans (CBLB500 and CBLB600 series) are modified proteins of microbes and tumors that protect cells from apoptosis, and, as a result, have a broad spectrum of potential applications. These potential applications include both non-medical applications such as protection from exposure to radiation, whether as a result of military or terrorist action or as a result of a nuclear accident, as well as medical applications such as reducing cancer treatment side effects.

The Company recently submitted data on its Protectan compounds in response to a Request for Information (RFI), issued by the Department of Health and Human Services (DHHS), for medical countermeasures to address chemical, biological, radiological and nuclear (CBRN) threats. CBLI is also in contract negotiations with the Defense Threat Reduction Agency (DTRA) of the Department of Defense (DoD) for a developmental grant, which would establish a pathway for procurement.

Curaxins (CBLC100 series) are small molecules designed to kill tumor cells by simultaneously targeting two regulators of apoptosis. Initial test results indicate that Curaxins can be effective against a number of malignancies, including renal cell carcinoma, or RCC (a highly fatal form of kidney cancer), soft-tissue sarcoma and hormone refractory prostate cancer. The FDA has approved a Phase II efficacy study for advanced, refractory prostate cancer at the Cleveland Clinic and Case Western Reserve University Hospital and enrollment will start shortly.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at

This press release contains forward-looking statements that reflect our current view with respect to various aspects of the events described above. Actual results could be significantly different. Factors that could affect results include those set forth in filings made by Cleveland BioLabs, Inc. with the Securities and Exchange Commission. These factors include, but are not limited to, those discussed in our Registration Statement on Form SB-2 under the caption "Risk Factors."

    The Global Consulting Group
    Rachel Levine
    T: (646) 284-9439